Call toll-free 800.328.1267

Insights AI

The market’s most important stocks, simplified

Hims & Hers Health (HIMS) has achieved impressive revenue growth of 49.16% as of September 30, 2025, surpassing industry averages in the healthcare sector. However, profitability remains a challenge, with a net margin of 2.63% below industry standards and a return on assets (ROA) of 0.77%. While the return on equity (ROE) of 2.76% is above industry norms, the company's debt-to-equity ratio of 1.92 indicates higher financial leverage compared to peers, raising concerns about its financial stability. Analyst ratings for HIMS are mixed, reflecting these challenges. Glen Santangelo of Barclays rates the stock "Overweight" with a $48.00 price target, while David Larsen of BTIG maintains a "Buy" rating but has lowered the target from $85.00 to $60.00. Mark Mahaney of Evercore ISI Group gives an "In-Line" rating with a $33.00 target, and Allen Lutz of B of A Securities has downgraded the stock to "Underperform," reducing the target from $26.00 to $21.00. The average 12-month price target has dropped by 27.03%, from $55.50 to $40.50, reflecting concerns over profitability and debt levels despite strong revenue growth.
Source content provided by Benzinga.
This content was created in whole or in part using Generative Artificial Intelligence (AI). Please read the disclosures found at the end of this content for more information.

Ready to make your move?

You’ve seen the news. It’s time to set your strategy. The TradeStation ecosystem is designed to execute your trades no matter how unique or complex. Set your strategy in motion with the advanced tools and brokerage services built specifically for those who are born to trade

Recent news for HIMS

News in this section is provided by Benzinga and is written entirely by Benzinga authors. Articles are presented as they were provided by Benzinga, and do not represent the opinions of TradeStation or its employees.

By clicking one of the links below, you are leaving TradeStation.com.

Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More

Here's a look at the top ten. most shorted stocks in the market, including Lucid, Hims & Hers and CleanSpark.

Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market

Novo Nordisk plans to sell Wegovy in vials in the U.S., expanding options as it competes with Eli Lilly in the growing weight-loss drug market.

Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs

Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year.

About HIMS

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include ... Read more

Ways to trade options* on HIMS

Bearish Option Strategy: Long Puts

Traders buy a single put option on a stock or ETF. This strategy can benefit from a price drop while risking more capital than a spread.

Learn more

  • 1
  • 2
  • 3

Insights AI filters through the noise to uncover meaningful data that natural-born traders can use to find new trading opportunities. Our AI model distills complex market news and data into accessible, actionable intelligence. Stay informed of market moves with curated trading intelligence and platform tips delivered directly to you.

Market Insights, Insights AI, and all related pages and content are hosted by TradeStation Group, Inc.

The symbols selected include stocks that meet a specific set of criteria: the 50 most active stocks based on 21-day options volume. ETFs and meme stocks are not included.

This Content was created in whole or in part using Generative Artificial Intelligence (AI). While efforts have been made to ensure accuracy, the Content is generated autonomously by AI algorithms and it may contain errors or inaccuracies. Users are advised to critically evaluate the information presented.

This Content is for educational and informational purposes only. Any symbols or trading strategies discussed are for demonstration purposes only and are not research or recommendations.

TradeStation Group, Inc. (“TradeStation”) pays third parties for the data and other information included on this page (the “Content”). The Content is derived from news and other information feeds provided by Accretive Capital LLC d/b/a Benzinga (“Benzinga”) and market activity. Benzinga is not affiliated with TradeStation. TradeStation makes the Content available for informational purposes only. The Content should not be considered an offer or solicitation tobuy, sell, or hold any investment/security. The Content is believed to be from reliable sources; however, TradeStation does not verify all of the information included in the Content for accuracy or completeness. TradeStation does not endorse any third-party content, and any views or opinions expressed in the Content do not necessarily represent the views and opinions of TradeStation. Any goods or services offered by Benzinga are not sponsored, endorsed, sold, or promoted by TradeStation, and TradeStation makes no representation regarding any such goods or services.

TradeStation does not endorse or adopt the Content, and makes no guarantees that the Content is accurate, complete, or timely. TradeStation assumes no responsibility for the accuracy, completeness, updates, changes, or timeliness of the Content. TradeStation does not provide investment, tax or legal advice. Any recommendation, opinion or advice regarding securities or markets contained in the Content does not reflect the views of TradeStation. TradeStation assumes no responsibility for any fact, recommendation, opinion or advice contained in the Content and expressly disclaims any responsibility for any decisions based upon any such Content.

Any decisions you may make to buy, sell or hold a security or other investment based on the Content or other third-party information will be entirely your own and not in any way deemed to be endorsed, influenced by or attributed to TradeStation. It is understood that, without exception, any order based on the Content that is placed with TradeStation for execution should be considered by you to be an unrecommended and unsolicited order. TradeStation will treat all such orders as unsolicited.

*Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com/DisclosureOptions. Visit www.TradeStation.com/Pricing for full detailson the costs and fees associated with options.